TransCode Therapeutics (RNAZ) Stock: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$1.69
0.00 (0.00%)
▲
5d:
-21.58%
30d:
-49.85%
90d:
-69.33%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNAZ is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNAZ is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $1.69, which is considered oversold relative to its 30-day fair value range of $2.02 to $3.73.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.63, while resistance sits at $2.35.
Market Sentiment: RNAZ scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+491.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. Immediate support is located at $1.63, while resistance sits at $2.35.
Market Sentiment: RNAZ scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+491.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.02 -
$3.73
Company Quality Score
39/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Trading 491.7% below Wall St target ($10.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.02 -
$3.73
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.63
Resistance Level
$2.35
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.28
Wall Street Target
$10.00
(+491.7%)
Share & Embed Analysis
Last updated: September 11, 2026 10:22 PM ET
Data refreshes hourly during market hours. Next update: 11:22 PM
Data refreshes hourly during market hours. Next update: 11:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
